Pfizer, Merck KGaA say their PD-L1 Bavencio also flunked PhIII in the all-important lung cancer field
Playing catch-up in the crowded PD-1/L1 field in cancer R&D is proving particularly tough for Merck KGaA and Pfizer $PFE.
The partners reported this morning …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
